Table 1 Demographic and clinical features of systemic sclerosis patients
| Â | dcSSc | lcSSc | Â | ||
|---|---|---|---|---|---|
Demographic and clinical features | Data | Range | Data | range | P-value |
Number of patients | 15 | 26 | Â | ||
Age (yrs; mean; SD) | 53 ± 13.1 | 28 to 71 | 52 ± 9.3 | 39 to 73 | NS |
M/F ratio | 2/13 | Â | 6/20 | Â | NS |
Disease duration (yrs; mean; SD) | 8 ± 3.3 | 2 to 15 | 8.5 ± 5.8 | 1 to 21 | NS |
Clinical manifestation | Â | Â | Â | ||
Raynaud phoenomenon | 15 (100%) | 23 (88%) | NS | ||
Teleangectasias | 10 (66%) | 9 (35%) | NS | ||
Lung involvement | 13 (87%) | 14 (54%) | NS | ||
Oesophagus involvement | 14 (93%) | 9 (35%) | 0.001 | ||
Trophic ulcers | 10 (66%) | 8 (31%) | 0.06 | ||
Calcinosis | 0 | 5 (19%) | NS | ||
Serological findings | Â | Â | Â | ||
Anti-Scl-70 | 12 (80%) | 10 (38%) | 0.02 | ||
Anti-Centromere | 0 | 6 (23%) | NS | ||
Risk factor for CAD | Â | Â | Â | ||
Hypertension | 4 (27%) | 9 (35%) | NS | ||
Diabetes | 2 (13%) | 2 (7%) | NS | ||
Hypercholesterolemia | 6 (40%) | 4 (15%) | NS | ||
Treatment | Â | Â | Â | ||
D-Penicillamine | 3 (19%) | 5 (19%) | NS | ||
Cyclophosphamide | 8 (50%) | 0 | 0.0004 | ||
Cyclosporine | 3 (19%) | 3 (11%) | NS | ||
Iloprost | 13 (87%) | 9 (35%) | 0.003 | ||
Steroids | 6 (37%) | 2 (7%) | 0.004 | ||
Calcium-blockers | 3 (19%) | 1 (3%) | NS | ||
ACE-inhibitors | 3 (19%) | 1 (3%) | NS | ||
Angiotensin II receptor blocker | 2 (13%) | 1 (3%) | NS | ||